Choice of Tyrosine Kinase Inhibitor (TKI) or Immune Check-point Inhibitor guided by dual-tracer (11C-acetate and 18F-FDG) PET/CT improves the progression-free survival in patients with advanced or metastatic HCC

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

You are going to email the following Choice of Tyrosine Kinase Inhibitor (TKI) or Immune Check-point Inhibitor guided by dual-tracer (11C-acetate and 18F-FDG) PET/CT improves the progression-free survival in patients with advanced or metastatic HCC

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.